JPRN-UMIN000000575已完成4 期
a multicenter, open-labeled, randomized, parallel-group study comparing fluticasone propionate nasal spray and oral fexofenadine hydrochroride as early seasonal treatment for Japanese cedar pollinosis - a randomized study comparing fluticasone propionate nasal spray and oral fexofenadine hydrochroride as early seasonal treatment for Japanese cedar pollinosis (FOREST study)
Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi0 个研究点目标入组 120 人开始时间: 2007年1月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) use of any anti-allergy drugs at the beginning of the study 2) any other nose/paranasal sinus disease, pharyngitis, laryngitis, respiratory tract infection, asthma 3) a history of glaucoma, gastric ulcer, uncontrollable hypertension/diabetes, hepatitis, malignant tumor 4) buildup phase of specific immunotherapy to Japanese cedar pollen 5) a history of nose/paranasal sinus surgery 6) a history of hypersensitivity to fluticasone propionate or fexofenadine hydrochroride 7) pregnancy, potential pregnancy, or lactation
研究者
相似试验
进行中（未招募）
不适用
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 7.0Level: pr tClassification code 10060862Prostate cancerEUCTR2005-005595-33-DEFerring Pharmaceuticals A/S600
进行中（未招募）
不适用
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 7.0Level: pr tClassification code 10060862Prostate cancerEUCTR2005-005595-33-CZFerring Pharmaceuticals A/S600
进行中（未招募）
不适用
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation TherapyMedDRA version: 7.0Level: pr tClassification code 10060862Prostate cancerEUCTR2005-005595-33-HUFerring Pharmaceuticals A/S540
进行中（未招募）
1 期
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation TherapyProstate cancerEUCTR2005-005595-33-GBFerring Pharmaceuticals A/S540
已完成
不适用
IDPN-2Chronic kidney diseaseJPRN-jRCTs031220296Kanno Yoshihiko40